Market research
IKNA Ikena Oncology Inc
NASDAQ USD Healthcare
Latest close
As of 22 Aug 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 719M
- P/E ratio
- Not available
- Analyst target
- 276.0001
- Dividend yield
- Not available
- Beta
- 0.5
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 719M
- P/E ratio
- Not available
- Analyst target
- 276.0001
- Dividend yield
- Not available
- Beta
- 0.5
About
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmaceuticals Co. Ltd.
Research context
Ikena Oncology Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IKNA discussion.
5 years, 7 months ago
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.6.
Based on the above factors, Ikena Oncology, Inc. Common Stock gets an overall score of 1/5.